Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human,Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch.

Trial Profile

First-in-human,Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Aug 2018

At a glance

  • Drugs SNA 125 (Primary)
  • Indications Pruritus; Psoriasis
  • Focus Adverse reactions; First in man; Proof of concept
  • Most Recent Events

    • 27 Aug 2018 Results presented in a Sienna Biopharmaceuticals media release
    • 14 Feb 2018 According to a Sienna Biopharmaceuticals media release, first patient has been dosed and expect to report top-line data in the third quarter of 2018
    • 14 Feb 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top